Compare LDI & RXST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LDI | RXST |
|---|---|---|
| Founded | 2010 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 536.2M | 524.6M |
| IPO Year | 2021 | 2021 |
| Metric | LDI | RXST |
|---|---|---|
| Price | $2.62 | $9.49 |
| Analyst Decision | Sell | Hold |
| Analyst Count | 3 | 11 |
| Target Price | $3.00 | ★ $11.40 |
| AVG Volume (30 Days) | ★ 4.7M | 935.1K |
| Earning Date | 03-10-2026 | 02-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,095,780,000.00 | $142,085,000.00 |
| Revenue This Year | $28.65 | N/A |
| Revenue Next Year | $16.88 | $4.12 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 10.74 | ★ 10.75 |
| 52 Week Low | $1.01 | $6.32 |
| 52 Week High | $5.05 | $34.71 |
| Indicator | LDI | RXST |
|---|---|---|
| Relative Strength Index (RSI) | 51.06 | 39.82 |
| Support Level | $2.55 | $9.47 |
| Resistance Level | $2.89 | $10.16 |
| Average True Range (ATR) | 0.24 | 0.61 |
| MACD | 0.03 | -0.02 |
| Stochastic Oscillator | 44.89 | 36.49 |
loanDepot Inc provides nonbank consumer lending solutions for individuals in the United States. It offers personal, residential home, home refinancing, mortgage and home equity loans. It also provides online mortgage loans for refinancing and home purchases. It serves customers through distribution channels, including consumer direct centres, retail branches, wholesale centres, and consumer finance and servicing centres in the United States. It competes with commercial banks and financial institutions.
RxSight Inc is a commercial-stage medical technology company dedicated towards improving the vision of patients following cataract surgery. It offers intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. The company operates and manages its business in one reportable segment, the research and development, manufacture and sale of light adjustable lenses and related capital equipment.